Aquestive Therapeutics, Inc. (AQST)
$
4.02
-0.12 (-2.99%)
Key metrics
Financial statements
Free cash flow per share
-0.4345
Market cap
399.2 Million
Price to sales ratio
8.9620
Debt to equity
-3.9048
Current ratio
3.1354
Income quality
0.6258
Average inventory
7 Million
ROE
1.9565
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aquestive Therapeutics, Inc. is a pharmaceutical company that specializes in identifying, developing, and commercializing innovative products to meet unmet medical needs both in the United States and internationally. The company has seen an interest income of $4,367,000.00 showcasing its financial investments. Its total costs and expenses amount to $115,596,000.00 reflecting the overall spending while the cost of revenue is $18,555,000.00 which highlights its production and operational expenses. Additionally, the company reported selling, general, and administrative expenses of $79,849,000.00 indicating its operational overhead costs. The weighted average number of diluted shares outstanding is $121,966,911.00 revealing potential dilution effects on shareholders. Among its marketed products are Sympazan, a clobazam treatment for Lennox-Gastaut syndrome, and Suboxone, a sublingual film for opioid dependence. Other products include Zuplenz, designed for nausea and vomiting related to chemotherapy, and Azstarys, a once-daily treatment for ADHD. The company's proprietary pipeline features Libervant, a buccal formulation of diazepam for seizures, and Exservan, a film formulation of riluzole for ALS. Additionally, it is developing AQST-108 and AQST-305, both sublingual film formulations targeting various health conditions, and KYNMOBI for Parkinson’s disease management. The stock is affordable at $5.67 making it suitable for budget-conscious investors. With a high average trading volume of 4,903,572.00 the stock indicates strong liquidity, attracting interest from various traders. Currently, the company's market capitalization stands at $399,212,677.00 classifying it as a small-cap player within the market. As a key player in the Drug Manufacturers - Specialty & Generic industry, Aquestive Therapeutics contributes significantly to the overall market landscape while driving innovation and growth within the Healthcare sector. This dynamic positioning underscores the company's commitment to addressing critical health challenges and expanding its presence in the pharmaceutical market.
Is Aquestive Therapeutics, Inc. (AQST) a good investment?
Investing in Aquestive Therapeutics, Inc. (AQST) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Aquestive Therapeutics, Inc. (AQST)'s stock forecast?
Analysts predict Aquestive Therapeutics, Inc. stock to fluctuate between $2.12 (low) and $7.55 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aquestive Therapeutics, Inc.'s market capitalization?
As of 2026-03-27, Aquestive Therapeutics, Inc.'s market cap is $399,212,677, based on 99,306,636 outstanding shares.
How does Aquestive Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Aquestive Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aquestive Therapeutics, Inc. (AQST) stock?
To buy Aquestive Therapeutics, Inc. (AQST) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AQST. Place an order (Market, Limit, etc.).
What is the best time to invest in Aquestive Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Aquestive Therapeutics, Inc. perform in the last earnings report?
Revenue: $44,545,000 | EPS: -$0.76 | Growth: 49.02%.
Where can I find Aquestive Therapeutics, Inc.'s investor relations reports?
Visit https://www.aquestive.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aquestive Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Aquestive Therapeutics, Inc. stock?
All-time high: $7.55 (2025-10-20) | All-time low: $0.62 (2022-07-01).
What are the key trends affecting Aquestive Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
NEW YORK, March 29, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the “Class Period”), of the important May 4, 2026 lead plaintiff deadline.
prnewswire.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 29, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
newsfilecorp.com
New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
prnewswire.com
NEW YORK, March 27, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. So What: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
globenewswire.com
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Aquestive Therapeutics, Inc. (NASDAQ: AQST).
newsfilecorp.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Aquestive between June 16, 2025 and January 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - March 27, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
newsfilecorp.com
New York, New York--(Newsfile Corp. - March 26, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, inclusive. Should You Join The Aquestive Class Action Lawsuit?
globenewswire.com
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Aquestive Class Action Lawsuit?
newsfilecorp.com
New York, New York--(Newsfile Corp. - March 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025 and January 8, 2026, both dates inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
globenewswire.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options
See all news
